Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-08-20
2010-06-22
Kolker, Daniel E. (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07741446
ABSTRACT:
The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5182107 (1993-01-01), Friden
patent: 5527288 (1996-06-01), Gross et al.
patent: 5562903 (1996-10-01), Co et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5656284 (1997-08-01), Balkin
patent: 5672683 (1997-09-01), Friden et al.
patent: 5824782 (1998-10-01), Holzer et al.
patent: 5848991 (1998-12-01), Gross et al.
patent: 5997501 (1999-12-01), Gross
patent: 6015662 (2000-01-01), Hackett
patent: 6041775 (2000-03-01), Century
patent: 6060069 (2000-05-01), Hill et al.
patent: 6248262 (2001-06-01), Kubotera et al.
patent: 6287792 (2001-09-01), Pardridge et al.
patent: 6322808 (2001-11-01), Trautman et al.
patent: 6329508 (2001-12-01), Friden
patent: 6348210 (2002-02-01), Gale
patent: 6361760 (2002-03-01), Murata et al.
patent: 6375975 (2002-04-01), Modi
patent: 6531309 (2003-03-01), Hu et al.
patent: 6582945 (2003-06-01), Raso
patent: 6709833 (2004-03-01), Fukul et al.
patent: 2002/0052311 (2002-05-01), Solomon et al.
patent: 2004/0101904 (2004-05-01), Pardridge et al.
patent: 2004/0248197 (2004-12-01), Holtzman et al.
patent: 2005/0142141 (2005-06-01), Pardridge
patent: 2008/0152645 (2008-06-01), Pardridge et al.
patent: 2008/0171055 (2008-07-01), Pardridge et al.
patent: 2008/0292639 (2008-11-01), Shen et al.
patent: 0 613 007 (1994-08-01), None
patent: 03/074081 (2003-12-01), None
Zhang 2001a (Journal of Neurochemistry 76:1597-1600).
Barth et al. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery. Mar. 1999;44(3):433-50; discussion 450-1.
Buchli, et al. Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system. Ann Med. 2005;37(8):556-67.
Deane, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci. 2005; 25(50):11495-503.
Manoutcharian, et al. Amyloid-beta peptide-specific single chain Fv antibodies isolated from an immune phage display library. J Neuroimmunol. 2003; 145(1-2):12-7.
Coloma, et al. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. Feb. 1997;15(2):159-63.
Ferber, D. Bridging the blood-brain barrier: new methods improve the odds of getting drugs to the brain cells that need them. PLoS Biol. Jun. 2007;5(6):e169: 1191-1194.
Marvin, et al. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin. Jun. 2005;26(6):649-58.
McGrath, et al. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J Neurosci Res. Jan. 15, 1997;47(2):123-33.
Arndt, et al. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma. Int J Cancer. Dec. 10, 2003;107(5):822-829.
Boado et al, Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnology and Bioengineering. 2007;97:1376-1386.
Boado et al. Fusion Antibody for Alzheimer's Disease with Bi-Directional Transport Across the Blood-Brain Barrier and Abeta Fibril Disaggregation. Bioconjug Chem. 2007;18(2):447-455.
Boado et al. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnology and Bioengineering. 2007;96:381-391.
Boado, et al. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng. Mar. 1, 2009;102(4):1251-8.
Brummell, et al. Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues. Biochemistry. 1993; 32(4)1180-7.
Coloma, et al. The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J Immunol. Jan. 15, 1997;158(2):733-40.
Deguchi, et al. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Jan.-Feb. 1999;10(1):32-7.
Forough, et al. Differential transforming abilities of non-secreted and secreted forms of human fibroblast growth factor-1. J Biol Chem. Feb. 5, 1993;268(4):2960-8.
Haisma, et al. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood. Jul. 1, 1998;92(1):184-90.
International search report dated Feb. 27, 2009 for PCT Application No. US08/71121.
International search report dated Jul. 1, 2008 for PCT Application No. US06/38587.
International Search Report dated Sep. 16, 2008 for PCT Application No. US2007/76316.
Lai, et al. Structural determinants of Trk receptor specificities using BDNF-based neurotrophin chimeras. J Neurosci Res. Dec. 1, 1996;46(5):618-29.
Office Action dated Jan. 15, 2008 for U.S. Appl. No. 11/245,710.
Office Action dated Jan. 23, 2009 for U.S. Appl. No. 11/245,546.
Office Action dated Apr. 13, 2007 for U.S. Appl. No. 11/245,710.
Office Action dated Jun. 3, 2008 for U.S. Appl. No. 11/245,710.
Office Action dated Jun. 17, 2009 for U.S. Appl. No. 11/841,541.
Office Action dated Jul. 2, 2008 for U.S. Appl. No. 11/245,546.
Office Action dated Jul. 2, 2009 for U.S. Appl. No. 11/245,710.
Office Action dated Jul. 31, 2009 for U.S. Appl. No. 12/179,806.
Office Action dated Aug. 20, 2009 for U.S. Appl. No. 12/323,232.
Office Action dated Sep. 20, 2007 for U.S. Appl. No. 11/245,710.
Office Action dated Oct. 15, 2007 for U.S. Appl. No. 11/245,710.
Office Action dated Oct. 20, 2009 for U.S. Appl. No. 11/245,546.
Office Action dated Oct. 30, 2009 for U.S. Appl. No. 11/841,592.
Office Action dated Nov. 8, 2007 for U.S. Appl. No. 11/245,546.
Office Action dated Nov. 10, 2008 for U.S. Appl. No. 11/245,710.
Office Action dated Nov. 13, 2006 for U.S. Appl. No. 11/245,710.
Padlan, et al. Identification of specificity-determining residues in antibodies. FASEB J. 1995; 9(1):133-9.
Pardridge, et al. 1998, Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration. Pharmaceutical Research 15 (4): 576-582.
Park, et al. Production and characterization of fusion proteins containing transferrin and nerve growth factor. J Drug Target. 1998;6(1):53-64.
Raghavan, et al. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry. Nov. 14, 1995;34(45):14649-57.
Triguero et al. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem. 1990; 54(6):1882-8.
Chen, et al. In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site. Protein Engineering. 1999; vol. 12, No. 4, 349-356.
Chung et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol. Feb. 2006:80(3 ):1340-51.
Coloma, M. Josephina, et al. 1999. Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor.Pharmaceutical Research17 (3): 266-274.
Duchnowska, et al. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Tread Rev. Jun. 2005;31(4)312-8.
Fukuda et al. In vitro evolution of single-chain antibodies using mRNA display. Nucleic Acids Research, 2006; 34(19):e127.
Hansson et al. Prediction of Alzhe
Boado Ruben J.
Pardridge William M.
Armagen Technologies, Inc.
Kolker Daniel E.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Fusion antibodies that cross the blood-brain barrier in both... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion antibodies that cross the blood-brain barrier in both..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion antibodies that cross the blood-brain barrier in both... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227370